I’m proud to share a huge new milestone in our journey: ActiGraph has officially rebranded to Ametris.
The decision to rebrand a company is never taken lightly, but this transformation reflects far more than just a new name and visual identity. It represents our evolution from a wearable device manufacturer supporting academic and public health research into a global digital health solutions provider.
When ActiGraph was officially founded in 2004, our goal was clear – to develop medical-grade wearable devices that deliver objective, real-world activity and sleep data to help academic researchers better understand human health and behavior. Over the past two decades, that mission has grown in both scope and ambition. We’ve continued to support academic and public health research with cutting-edge wearable technology, while also expanding our offerings to power global clinical trials with a sophisticated, integrated technology platform that spans device-based data collection, AI-driven analytics, regulatory alignment, and operational excellence.
Now, as Ametris (pronounced Uh-ME-tris), we carry forward everything that made ActiGraph successful while broadening our ability to meet the demands of modern clinical research.
[insert photo from conference presentation]
The shift to Ametris follows our acquisition of the Biofourmis Connect digital trial platform earlier this year. With this addition, our technology portfolio has significantly expanded, enabling us to offer a unified clinical trial ecosystem that supports both our proprietary devices and an array of validated third-party sensors, including EEG patches, digital spirometer, pulse oximeter, and blood pressure cuffs.
Now more than ever, we’re better equipped to partner with our academic and pharmaceutical partners in the important work of co-developing clinically validated outcome measures like we’ve done in our DECODE working groups and DEAR grant awards.
This means our partners can now depend on a single, scalable solution for capturing digital endpoints and biomarkers for precision at every phase of clinical development, powered by the same scientific rigor and deep operational expertise that ActiGraph built its reputation upon.
The new Ametris brand is more than a name and a new logo; it’s a statement of who we’ve evolved into after 20+ years at the forefront of our industry. Drawing on the Greek word for measurement, Ametris represents our commitment to precise, trustworthy data collection. We also share our new company name with a genus of moth, symbolizing transformation and purposeful navigation (and you’ll notice this inspired part of our new logo, as well).
The Ametris name embodies our commitment to transforming clinical trials into smarter, more patient-centered, and more evidence-driven endeavors. And it’s a tribute to the team, the clients, and the collaborators who’ve helped shape our journey every step of the way.
Of course, some things won’t change. Our mission, pioneering the digital transformation of clinical research, remains the same. Our standards for quality and innovation remain as high as ever. Our experienced team will continue to provide best-in-class scientific, technical, and regulatory support at every stage of every study. And to ensure continuity, our line of proprietary wearable devices and the ActiLife software will continue under the ActiGraph brand, maintaining consistency across scientific publications and regulatory submissions.
To our clients and partners: thank you for trusting us over the years. As Ametris, we look forward to what’s next with even more energy, expanded capabilities, and a renewed sense of purpose.
We’re not just changing our name. We’re stepping into a future we’ve spent two decades building. Here’s to the next phase.
For more information, read our recent press release, ActiGraph Rebrands as Ametris to Reflect Expanded Clinical Evidence Generation Capabilities